Design: The Pilot is designed to be a tolerability pilot where iTBS parameters are assessed in CD participants. The first half of the Pilot participants will be inpatient (for initial close observations) and the second half will be outpatient (closely reflecting the clinical trial). Throughout the Pilot, clinical measures will be collected and participants closely monitored. The general outline for the Clinical Trial is to characterize the treatment cohort (vs. HC) and assess effectiveness of iTBS over the left dlPFC in reducing cocaine use. The iTBS intervention consists of 30 sessions over a 2-week (10 treatment days) period as an add-on to a treatment-as-usual, contingency management. Structural and functional magnetic resonance imaging, neural measures of cue reactivity, reward processing, executive control, intrinsic network connectivity along with cardiac measures will be collected to identify differences between CD and HC participants at baseline. In CD participants, neural and cardiac measure along with cocaine use will be tracked longitudinally to assess changes with treatment. Contingency management will continue for 13 weeks and a 3-month follow-up will be scheduled. The Clinical Trial includes 39 visits.